SCHEMBL4858175

SCHEMBL4858175

OC1CCC(Nc2ncc3cc(Oc4ccc(F)cc4F)ccc3n2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.60
MAPK8 P45983 8/20 0.54
MAPK9 P45984 3/20 0.47
MAPK10 P53779 3/20 0.47
GAK O14976 1/20 0.47
RPS6KA4 O75676 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
MAPK1 P28482 1/20 0.47
CSNK1D P48730 1/20 0.47
RPS6KA3 P51812 1/20 0.47
DDR1 Q08345 1/20 0.47
MAPK11 Q15759 1/20 0.47
TAOK1 Q7L7X3 1/20 0.47
COQ8A Q8NI60 1/20 0.47
PRKD2 Q9BZL6 1/20 0.47
STK36 Q9NRP7 1/20 0.47
NLK Q9UBE8 1/20 0.47
LCK P06239 1/20 0.44
ITK Q08881 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14003196 0.90 MAPK8 (0.59) MAPK14MAPK8MAPK9MAPK10GAK
SCHEMBL5260841 0.86 MAPK14 (0.60) MAPK14MAPK8MAPK9MAPK10GAK
SCHEMBL14457338 0.85 MAPK8 (0.52) MAPK14MAPK8MAPK9MAPK10GAK
SCHEMBL14003195 0.82 MAPK8 (0.67) MAPK14MAPK8MAPK9MAPK10GAK
SCHEMBL4859569 0.81 MAPK8 (0.69) MAPK14MAPK8MAPK9MAPK10GAK
SCHEMBL14003166 0.79 MAPK14 (0.55) MAPK14MAPK8MAP4K4
SCHEMBL559211 0.78 MAPK8 (0.54) MAPK14MAPK8MAPK9MAPK10LCK
SCHEMBL559210 0.78 MAPK8 (0.54) MAPK14MAPK8MAPK9MAPK10LCK
SCHEMBL14014642 0.75 MAPK14 (1.00) MAPK14MAPK8MAPK9MAPK10GAK
SCHEMBL4860231 0.73 SCN9A (0.46) MAPK14MAPK8MAPK9MAPK10RPS6KA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456185-B2 Substituted quinazoline compounds useful as p38 kinase inhibitors ROCHE PALO ALTO LLC (US) 2008-11-25 US disclosed
US-20070167471-A1 Substituted quinazoline compounds useful as p38 kinase inhibitors DUNN JAMES P 2007-07-19 US disclosed
US-7238698-B2 Substituted quinazoline compounds useful as p38 kinase inhibitors ROCHE PALO ALTO LLC (US) 2007-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167471-A1 Substituted quinazoline compounds useful as p38 kinase inhibitors MAPK1, MAPK7, MAPK3 MAPK14 12/4885MAPK8 5/4885MAPK9 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.